DBeQ

DBeQ Basic information
Product Name:DBeQ
Synonyms:DBeQ;2,4-QuinazolinediaMine, N2,N4-bis(phenylMethyl)-;2,4-QuinazolinediaMine, N,N'-bis(phenylMethyl)-;JRF 12;N,N'-Dibenzylquinazoline-2,4-diamine;N2,N4-Dibenzylquinazoline-2,4-diamine;JRF;N,N'-Dibenzylquinazoline-2,4-diamine DBeQ
CAS:177355-84-9
MF:C22H20N4
MW:340.42
EINECS:
Product Categories:API;Inhibitors
Mol File:177355-84-9.mol
DBeQ Structure
DBeQ Chemical Properties
Melting point 149 °C
Boiling point 573.1±52.0 °C(Predicted)
density 1.259±0.06 g/cm3(Predicted)
storage temp. room temp
solubility DMSO: ≥20mg/mL
pka7.78±0.30(Predicted)
form powder
color white to beige
Stability:Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months.
InChIKeyQAIMUUJJAJBPCL-UHFFFAOYSA-N
CAS DataBase Reference177355-84-9
Safety Information
Hazard Codes Xn
Risk Statements 22-36
Safety Statements 26
WGK Germany 3
HS Code 2933.59.8000
MSDS Information
DBeQ Usage And Synthesis
DescriptionDBeQ (177355-84-9) is a potent, selective and reversible inhibitor of the AAA-ATPase p97 (ATPase associated with diverse cellular activities). Ki=3.2 μM. DBeQ blocks ubiquitin-dependent protein clearance pathways. Cell permeable.
UsesThe ATPase p97 is an ubiquitin-selective chaperone known to play a critical role in the degradation of misfolded membrane and secretory proteins and has been linked to various cellular processes that require unfolding and disassembly of protein complexes. DBeQ is a selective, reversible, and ATP-competitive inhibitor of the ATPase p97 (Ki = 3.2 μM; IC50 = 1.5 μM). It does not exhibit activity when tested against a panel 170 protein kinases at concentrations as high as 15 μM. At 10 μM it blocks endoplasmic reticulum-associated degradation, impairing the autophagy pathway and promoting the activation of caspase-3 and -7 in cancer cells.[Cayman Chemical]
UsesHeLa cells were treated with DBeQ and the effects on in vivo ubiquitination and protein dislocation were studied by live cell imaging.
Biochem/physiol ActionsDBeQ is a potent and specific inhibitor of ATPase p97, an integral component of the ubiquitin-fusion degradation (UFD) pathway. DBeQ inhibits the degradation of ubiquitinated proteins, the endoplasmic reticulum-associated degradation pathway, and autophagosome maturation. The compound also potently inhibits cellular proliferation and induces caspase 3/7 activity and apoptosis.
storageStore at +4°C
References1) Chou et al. (2011), Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways; Proc. Natl. Acad. Sci. USA, 108 4834
DBeQ Preparation Products And Raw materials
4-BroMo-N-(4-broMophenyl)-3-[[(phenylMethyl)aMino]sulfonyl]benzaMide LLY-507 Givinostat (ITF2357) Veliparib indoleaMine-2,3-dioxygenase inhibitor INCB024360 BAFILOMYCIN A1 Fingolimod hydrochloride Epacadostat (INCB024360) Enasidenib 3,4-dimethoxy-N-[4-(3-nitrophenyl)-1,3-thiazol-2-yl]benzenesulfonamide 2-(2-Chlorophenyl)-4-(3-(diMethylaMino)phenyl)-5-Methyl-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione MS023 Cabozantinib SGC707 Ezetimibe NMS 873 Pevonedistat AZD6738

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.